352 related articles for article (PubMed ID: 35045875)
1. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
2. Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D; Mesa R
Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
[TBL] [Abstract][Full Text] [Related]
3. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian JJ; Lech-Maranda E; McLornan D; Vannucchi AM; Platzbecker U; Huang M; Strouse B; Klencke B; Verstovsek S
Leukemia; 2022 Sep; 36(9):2261-2268. PubMed ID: 35869266
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
6. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
7. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
Duminuco A; Chifotides HT; Giallongo S; Giallongo C; Tibullo D; Palumbo GA
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201581
[TBL] [Abstract][Full Text] [Related]
8. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Oh ST; Talpaz M; Gerds AT; Gupta V; Verstovsek S; Mesa R; Miller CB; Rivera CE; Fleischman AG; Goel S; Heaney ML; O'Connell C; Arcasoy MO; Zhang Y; Kawashima J; Ganz T; Kowalski M; Brachmann CB
Blood Adv; 2020 Sep; 4(18):4282-4291. PubMed ID: 32915978
[TBL] [Abstract][Full Text] [Related]
9. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
[TBL] [Abstract][Full Text] [Related]
10. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
11. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.
Asshoff M; Petzer V; Warr MR; Haschka D; Tymoszuk P; Demetz E; Seifert M; Posch W; Nairz M; Maciejewski P; Fowles P; Burns CJ; Smith G; Wagner KU; Weiss G; Whitney JA; Theurl I
Blood; 2017 Mar; 129(13):1823-1830. PubMed ID: 28188131
[TBL] [Abstract][Full Text] [Related]
12. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
13. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
Kiladjian JJ; Vannucchi AM; Gerds AT; Gupta V; Verstovsek S; Egyed M; Platzbecker U; Mayer J; Grosicki S; Illés Á; Woźny T; Oh ST; McLornan D; Kirgner I; Yoon SS; Harrison CN; Klencke B; Huang M; Kawashima J; Mesa R
Hemasphere; 2023 Nov; 7(11):e963. PubMed ID: 37908862
[TBL] [Abstract][Full Text] [Related]
14. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Gerds AT; Verstovsek S; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Oh S; Klencke BJ; Yu J; Donahue R; Kawashima J; Mesa R
Lancet Haematol; 2023 Sep; 10(9):e735-e746. PubMed ID: 37517413
[TBL] [Abstract][Full Text] [Related]
15. Momelotinib for the treatment of myelofibrosis.
Xu L; Feng J; Gao G; Tang H
Expert Opin Pharmacother; 2019 Nov; 20(16):1943-1951. PubMed ID: 31450973
[No Abstract] [Full Text] [Related]
16. Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus.
Klencke BJ; Donahue R; Gorsh B; Ellis C; Kawashima J; Strouse B
Future Oncol; 2024 Apr; 20(11):703-715. PubMed ID: 38318719
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Mesa RA; Hudgens S; Floden L; Harrison CN; Palmer J; Gupta V; McLornan DP; McMullin MF; Kiladjian JJ; Foltz L; Platzbecker U; Fox ML; Mead AJ; Ross DM; Oh ST; Perkins A; Leahy MF; Deheshi S; Donahue R; Klencke BJ; Verstovsek S
Cancer Med; 2023 May; 12(9):10612-10624. PubMed ID: 37021939
[TBL] [Abstract][Full Text] [Related]
18. Momelotinib: First Approval.
Keam SJ
Drugs; 2023 Dec; 83(18):1709-1715. PubMed ID: 37989928
[TBL] [Abstract][Full Text] [Related]
19. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Chifotides HT; Masarova L; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
[TBL] [Abstract][Full Text] [Related]
20. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
